January 18, 2017 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Derma Sciences Inc (NASDAQ:DSCI), was announced concerning whether the takeover of Derma Sciences Inc. by LifeSciences Holdings Corporation is unfair to NASDAQ:DSCI stockholders.

The investigation by a law firm concerns whether certain officers and directors of Derma Sciences Inc breached their fiduciary duties owed to NASDAQ:DSCI investors in connection with the proposed acquisition.

On January 10, 2017, Derma Sciences Inc (NASDAQ:DSCI) announced that it has signed an agreement whereby Derma Sciences will be acquired by Integra LifeSciences Holdings Corporation(Nasdaq: IART) for $7.00 per share of common stock in cash, or a total of approximately $204 million, and $32.00 per share for its outstanding shares of Series A Convertible Preferred Stock and $48.00 per share for its Series B Convertible Preferred Stock, reflecting the stated value of such preferred stock in each case.

However, given that at least one analyst has set the high target price for NASDAQ:DSCI shares at $8.50 per share, the investigation concerns whether the offer is unfair to Derma Sciences Inc (NASDAQ:DSCI stockholders. More specifically, the investigation concerns whether the Derma Sciences Inc (NASDAQ:DSCI Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Derma Sciences Inc reported that its annual Total Revenue rose from $83.75 million in 2014 to $84.47 million in 2015. Shares of Derma Sciences Inc (NASDAQ:DSCI) reached in 2014 as high as $15.21 per share.

On January 18, 2017, NASDAQ:DSCI shares closed at $7.00 per share